Trade Cytori Therapeutics - PSTV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.62 |
| Open | 1.59 |
| 1-Year Change | 318.42% |
| Day's Range | 1.58 - 1.65 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 1.62 | 0.03 | 1.89% | 1.59 | 1.62 | 1.52 |
| Apr 24, 2024 | 1.58 | 0.00 | 0.00% | 1.58 | 1.58 | 1.48 |
| Apr 23, 2024 | 1.61 | 0.06 | 3.87% | 1.55 | 1.64 | 1.55 |
| Apr 22, 2024 | 1.62 | 0.02 | 1.25% | 1.60 | 1.70 | 1.50 |
| Apr 19, 2024 | 1.61 | -0.07 | -4.17% | 1.68 | 1.68 | 1.60 |
| Apr 18, 2024 | 1.68 | -0.03 | -1.75% | 1.71 | 1.75 | 1.66 |
| Apr 17, 2024 | 1.71 | -0.01 | -0.58% | 1.72 | 1.77 | 1.65 |
| Apr 16, 2024 | 1.72 | 0.00 | 0.00% | 1.72 | 1.73 | 1.71 |
| Apr 15, 2024 | 1.72 | -0.05 | -2.82% | 1.77 | 1.78 | 1.68 |
| Apr 12, 2024 | 1.84 | 0.06 | 3.37% | 1.78 | 1.87 | 1.76 |
| Apr 11, 2024 | 1.81 | 0.05 | 2.84% | 1.76 | 1.84 | 1.76 |
| Apr 10, 2024 | 1.78 | 0.00 | 0.00% | 1.78 | 1.84 | 1.76 |
| Apr 9, 2024 | 1.80 | -0.02 | -1.10% | 1.82 | 1.84 | 1.80 |
| Apr 8, 2024 | 1.84 | 0.02 | 1.10% | 1.82 | 1.84 | 1.76 |
| Apr 5, 2024 | 1.86 | -0.03 | -1.59% | 1.89 | 1.94 | 1.81 |
| Apr 4, 2024 | 1.86 | -0.04 | -2.11% | 1.90 | 1.91 | 1.85 |
| Apr 3, 2024 | 1.86 | 0.01 | 0.54% | 1.85 | 1.91 | 1.81 |
| Apr 2, 2024 | 1.82 | 0.01 | 0.55% | 1.81 | 1.84 | 1.77 |
| Apr 1, 2024 | 1.78 | 0.01 | 0.56% | 1.77 | 1.79 | 1.73 |
| Mar 28, 2024 | 1.76 | -0.02 | -1.12% | 1.78 | 1.82 | 1.74 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cytori Therapeutics Company profile
About Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Plus Therapeutics Inc revenues decreased from $303K to $0K. Net loss increased 63% to $13.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 97% to $5.2M (expense), Change in fair value of liability instru decrease of 100% to $6K (income).
Equity composition
Common Stock $.001 Par, 02/11, 95M auth., 51,963,679 issd. Insiders own 14.62% IPO:N/A. 05/16, 1-for-15 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
4200 Marathon Blvd Ste 200
AUSTIN
TEXAS 78756-3433
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com